5-Amino-1MQ

Investigated uses

• No adequately documented human investigated use for the exact catalog identity/formulation was identified; any vendor-promoted goals were excluded from evidence grading.

Mechanism and hypotheses

• 5-Amino-1MQ is a membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT) in preclinical systems.
• Hypothesized: Metabolic and adiposity effects are hypothesized to follow altered methyl-donor and NAD-related metabolism; evidence in the catalog context remains animal-only.

Human evidence

• No qualifying controlled human trial was identified; anti-obesity findings are from mouse models. Limitations: Animal dosing and metabolism do not establish a human dose or safety margin.

Safety highlights

• Unknown or insufficiently characterized for the exact catalog product.
• Identity, purity, sterility, endotoxin, aggregation, immunogenicity, concentration and route-specific risks are not adequately characterized.

Regulatory context

No FDA-approved product matching the exact catalog presentation was identified in this review.